These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11718702)

  • 1. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood.
    Jung K; Lein M; Laube C; Lichtinghagen R
    Clin Chim Acta; 2001 Dec; 314(1-2):241-4. PubMed ID: 11718702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices.
    Mannello F; Tanus-Santos JE; Meschiari CA; Tonti GA
    Anal Biochem; 2008 Mar; 374(1):56-63. PubMed ID: 18082127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
    Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
    Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood.
    Mannello F; Jung K; Tonti GA; Canestrari F
    Clin Biochem; 2008 Dec; 41(18):1466-73. PubMed ID: 18926810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.
    Gerlach RF; Demacq C; Jung K; Tanus-Santos JE
    Clin Biochem; 2007 Jan; 40(1-2):119-23. PubMed ID: 17150202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anticoagulants on the activity of gelatinases.
    Castellazzi M; Tamborino C; Fainardi E; Manfrinato MC; Granieri E; Dallocchio F; Bellini T
    Clin Biochem; 2007 Nov; 40(16-17):1272-6. PubMed ID: 17904541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
    Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
    Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors.
    Rossignol P; Cambillau M; Bissery A; Mouradian D; Benetos A; Michel JB; Plouin PF; Chatellier G; Jacob MP
    Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):464-9. PubMed ID: 18307742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology.
    Thrailkill KM; Moreau CS; Cockrell G; Simpson P; Goel R; North P; Fowlkes JL; Bunn RC
    Clin Chem Lab Med; 2005; 43(12):1392-9. PubMed ID: 16309379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis.
    Olson FJ; Schmidt C; Gummesson A; Sigurdardottir V; Hulthe J; Wiklund O; Fagerberg B
    J Intern Med; 2008 Jun; 263(6):626-35. PubMed ID: 18341531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reference intervals of plasma matrix metalloproteinases 2, 3, and 9 and serum asymmetric dimethylarginine levels.
    Kusnierova P; Vsiansky F; Pleva L; Plevova P; Safarcik K; Svagera Z
    Scand J Clin Lab Invest; 2015 Oct; 75(6):508-13. PubMed ID: 26151887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
    Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
    Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma.
    Di Carlo A
    Oncol Rep; 2012 Sep; 28(3):1051-6. PubMed ID: 22711190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities.
    Gerlach RF; Uzuelli JA; Souza-Tarla CD; Tanus-Santos JE
    Anal Biochem; 2005 Sep; 344(1):147-9. PubMed ID: 15950912
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients.
    Sauer CG; Kappeler A; Späth M; Kaden JJ; Michel MS; Mayer D; Bleyl U; Grobholz R
    Virchows Arch; 2004 Jun; 444(6):518-26. PubMed ID: 15088144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological weakness in using correlation coefficients for assessing the interchangeability of analyte data between samples collected under different sampling conditions--the example of matrix metalloproteinase 9 determined in serum and plasma samples.
    Jung K; Wu CY
    Clin Chem Lab Med; 2010 May; 48(5):733-6. PubMed ID: 20192882
    [No Abstract]   [Full Text] [Related]  

  • 18. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
    Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
    Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method.
    Niedworok C; vom Dorp F; Tschirdewahn S; Rübben H; Reis H; Szucs M; Szarvas T
    Int Urol Nephrol; 2016 Mar; 48(3):355-61. PubMed ID: 26725072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of different anticoagulants in test tubes for analysis of blood lactate concentrations: Part 2. Implications for the proper handling of blood specimens obtained from critically ill patients.
    Wiese J; Didwania A; Kerzner R; Chernow B
    Crit Care Med; 1997 Nov; 25(11):1847-50. PubMed ID: 9366768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.